New Zealand markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.20+1.27 (+10.65%)
At close: 04:00PM EST
13.82 +0.62 (+4.70%)
After hours: 05:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close11.93
Open11.91
Bid11.89 x 900
Ask19.00 x 800
Day's range11.69 - 13.35
52-week range11.69 - 22.24
Volume182,559
Avg. volume106,069
Market cap426.672M
Beta (5Y monthly)1.53
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720

    CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero’s investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease. “We are very pleased with the FDA’s decision and eager to bring SPR720 back into the clinic,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero. “Extensive ana

  • GlobeNewswire

    Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis

    The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment in adult patients with complicated urinary tract infections (c

  • GlobeNewswire

    Spero Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Piper Sandler 33rd Annua